Geoff Pardo

Geoff Pardo is a General Partner Healthtech in Gilde Healthcare’s Venture&Growth team. He joined Gilde Healthcare in 2011 and oversees investments across the Venture&Growth fund in North America. Gilde describes the strategy as focused on healthtech and therapeutics, backing early-revenue or clinical-development-stage companies in Europe and North America with equity investments of up to €50 million per company.

Before Gilde, Pardo was a Partner at Spray Venture Partners, where he led medical-device investments including Interlace Medical, Solace Therapeutics, TearScience and Cascade Ophthalmics. He also served as President and CEO of Facet Solutions, a spinal implant company focused on lumbar spinal stenosis, until its sale to Globus Medical in 2011.

Earlier in his career, he worked at Cardinal Partners as an Associate leading medical-device investing activity and began in medical devices as a product manager at Synthes USA. He holds a BA with honors in History from Brown University and an MBA from the Wharton School of Business.

Pardo is also the host of the MedTech Talk podcast, where he interviews medtech entrepreneurs, executives and investors. Public bios and Gilde portfolio pages identify him as a board representative or former board representative for companies including Mainstay Medical, Okami Medical, Shoulder Innovations, SpyGlass Pharma, Nalu Medical, Inari Medical, Axonics, CVRx, Ablative Solutions, Vesper Medical, InovaLabs, BionX and Vapotherm.

• Invests through Gilde Healthcare Venture&Growth, which focuses on “healthtech and therapeutics” and supports fast-growing companies in Europe and North America.
• Targets early-revenue-stage or clinical-development-stage companies, not idea-stage seed companies.
• Gilde’s stated healthcare mission is investing in businesses that enable “better care at lower cost.”
• Typical investment structure is significant minority ownership, with equity investments of up to €50 million per portfolio company.
• Pardo’s own deal commentary emphasizes differentiated technology, de-risked clinical programs, large market opportunity, commercial expansion, reimbursement coverage and measurable patient impact.
• In medtech, his public track record clusters around neuromodulation, cardiovascular, orthopedic, ophthalmology, respiratory and surgical/device-enabled care models.